EUROSIDA Kohorte

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

A GSK1349572 Open label Protocol for HIV infectected, Adult patients with Integrase Resistance

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

A randomised, open-label study to examine the effectiveness and safety of Maraviroc (MVC) as a substitute for a nucleoside or nucleotide analogue reverse transcriptase inhibitor (N(t)RTI) or enhanced protease inhibitor (PI/r) for patients with HIV-1 infection and stable, well-controlled plasma HIV-RNA who simultaneously receive the first N(t)RTI + PI/r regimen of a combined anti-retroviral therapy (cART).

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

A multicenter, open-label, non-randomized trial to evaluate treatment with multi-drug class (MDC) HAART and its impact on the decay rate of latently infected CD4+ T cells

PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects.